Intranasal Oxytocin in Children and Adolescents with Autism Spectrum Disorder.

ABSTRACT:

Background

Experimental studies and small clinical trials have suggested that treatment with intranasal oxytocin may reduce social impairment in persons with autism spectrum disorder. Oxytocin has been administered in clinical practice to many children with autism spectrum disorder.

Methods

We conducted a 24-week, placebo-controlled phase 2 trial of intranasal oxytocin therapy in children and adolescents 3 to 17 years of age with autism spectrum disorder. Participants were randomly assigned in a 1:1 ratio, with stratification according to age and verbal fluency, to receive oxytocin or placebo, administered intranasally, with a total target dose of 48 international units daily. The primary outcome was the least-squares mean change from baseline on the Aberrant Behavior Checkl

SUBMITTER: Sikich L 

PROVIDER: S-EPMC9701092 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature